Reviewing Kyverna Therapeutics (KYTX) and Its Peers

Kyverna Therapeutics (NASDAQ:KYTX) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Kyverna Therapeutics to related businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, dividends, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations for Kyverna Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	0	1	5	1	3.00
Kyverna Therapeutics Competitors	1961	5432	14022	300	2.58

Kyverna Therapeutics presently has a consensus target price of $18.33, indicating a potential upside of 885.66%. As a group, “Biological products, except diagnostic” companies have a potential upside of 129.32%. Given Kyverna Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than its peers.

Volatility and Risk

Kyverna Therapeutics has a beta of 2.57, suggesting that its stock price is 157% more volatile than the S&P 500. Comparatively, Kyverna Therapeutics’ peers have a beta of -4.48, suggesting that their average stock price is 548% less volatile than the S&P 500.

Insider & Institutional Ownership

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Kyverna Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-51.12%	-37.91%
Kyverna Therapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Valuation and Earnings

This table compares Kyverna Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyverna Therapeutics	$7.03 million	-$60.37 million	-0.54
Kyverna Therapeutics Competitors	$575.27 million	-$70.96 million	-0.38

Kyverna Therapeutics’ peers have higher revenue, but lower earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Kyverna Therapeutics beats its peers on 9 of the 13 factors compared.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.